HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells

被引:236
|
作者
Boasso, Adriano
Herbeuval, Jean-Philippe
Hardy, Andrew W.
Anderson, Stephanie A.
Dolan, Matthew J.
Fuchs, Dietmar
Shearer, Gene M.
机构
[1] NCI, NIH, Expt Immunol Branch, Bethesda, MD 20815 USA
[2] Univ Paris 05, Hop Necker, CNRS, UMR 8147, Paris, France
[3] Wilford Hall USAF Med Ctr, Henry M Jackson Fdn, Lackland AFB, TX 78236 USA
[4] Wilford Hall USAF Med Ctr, Infect Dis Serv, Lackland AFB, TX 78236 USA
[5] Wilford Hall USAF Med Ctr, Infect Dis Serv, Lackland AFB, TX 78236 USA
[6] Innsbruck Med Univ, Div Biol Chem, Innsbruck, Austria
[7] Ludwig Boltzmann Inst AIDS Res, Innsbruck, Austria
关键词
D O I
10.1182/blood-2006-07-034785
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Infection with the human immunodeficiency virus type-1 (HIV) results in acute and progressive numeric loss of CD4(+) T-helper cells and functional impairment of T-cell responses. The mechanistic basis of the functional impairment of the surviving cells is not clear. Indoleamine 2,3-dioxygenase (IDO) is an immumosuppressive enzyme that inhibits T-cell proliferation by catabolizing the essential amino acid tryptophan (Trp) into the kynurenine (kyn) pathway. Here, we show that IDO mRNA expression is elevated in peripheral blood mononuclear cells (PBMCs) from HIV+ patients compared with uninfected healthy controls (HCs), and that in vitro inhibition of IDO with the competitive blocker 1-methyl tryptophan (1-mT) results in increased CD4(+) T-cell proliferative response in PBMCs from HIV-infected patients. We developed an in vitro model in which exposure of PBMCs from HCs to either infectious or noninfectious, R5- or X4-tropic HIV induced IDO in plasmacytoid dendritic cells (pDCs). HIV-induced IDO was not inhibited by blocking antibodies against interferon type I or type II, which, however, induced IDO in pDCs when added to PBMC cultures. Blockade of gp120/CD4 interactions with anti-CD4 Ab inhibited HIV-mediated IDO induction. Thus, induction of IDO in pDCs by HIV may contribute to the T-cell functional impairment observed in HIV/AIDS by a non-interferon-dependent mechanism.
引用
收藏
页码:3351 / 3359
页数:9
相关论文
共 50 条
  • [31] Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells
    Boasso, A
    Herbeuval, JP
    Hardy, AW
    Winkler, C
    Shearer, GM
    BLOOD, 2005, 105 (04) : 1574 - 1581
  • [32] IL-6 inhibits the tolerogenic function of CD8α+ dendritic cells expressing indoleamine 2,3-dioxygenase
    Grohmann, U
    Fallarino, F
    Bianchi, R
    Belladonna, ML
    Vacca, C
    Orabona, C
    Uyttenhove, C
    Fioretti, MC
    Puccetti, P
    JOURNAL OF IMMUNOLOGY, 2001, 167 (02): : 708 - 714
  • [33] Potential regulatory function of dendritic cells overexpression indoleamine 2,3-dioxygenase
    Funeshima, N
    Fujino, M
    Kitazawa, Y
    Okuyama, T
    Li, XK
    MOLECULAR THERAPY, 2004, 9 : S248 - S248
  • [34] Indoleamine 2,3-dioxygenase inhibits B cell immune response to T independent antigens
    Shinde, Rahul
    Chaudhary, Kapil
    Shimoda, Michiko
    Pacholczyk, Gabriela
    McGaha, Tracy
    JOURNAL OF IMMUNOLOGY, 2014, 192
  • [35] Gene silencing of indoleamine 2,3-dioxygenase 1 inhibits lung cancer growth by suppressing T-cell exhaustion
    Shang, Ke
    Wang, Zhigang
    Hu, Yinying
    Huang, Yanqin
    Yuan, Keng
    Yu, Yanrong
    ONCOLOGY LETTERS, 2020, 19 (06) : 3827 - 3838
  • [36] The subsets of dendritic cells and memory T cells correspond to indoleamine 2,3-dioxygenase in stomach tumor microenvironment
    Li, Fangxuan
    Huang, Jinchao
    Li, Shixia
    Li, Hui
    Yu, Jinpu
    Ren, Xiubao
    Liu, Juntian
    TUMOR BIOLOGY, 2014, 35 (09) : 8691 - 8698
  • [37] The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase
    Mads Hald Andersen
    Cancer Immunology, Immunotherapy, 2012, 61 : 1289 - 1297
  • [38] Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infection
    Fox, Julie M.
    Sage, Leo K.
    Huang, Lei
    Barber, James
    Klonowski, Kimberly D.
    Mellor, Andrew L.
    Tompkins, S. Mark
    Tripp, Ralph A.
    JOURNAL OF GENERAL VIROLOGY, 2013, 94 : 1451 - 1461
  • [39] The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase
    Andersen, Mads Hald
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (08) : 1289 - 1297
  • [40] Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
    Ninomiya, Soranobu
    Narala, Neeharika
    Huye, Leslie
    Yagyu, Shigeki
    Savoldo, Barbara
    Dotti, Gianpietro
    Heslop, Helen E.
    Brenner, Malcolm K.
    Rooney, Cliona M.
    Ramos, Carlos A.
    BLOOD, 2015, 125 (25) : 3905 - 3916